NCT03712488

Brief Summary

The investigator's goals in this study are to assess :

  1. 1.Differential expression of CD200 by using flow cytometric immune-phenotyping in broad range of patients with B-chronic lymphoproliferative disorders (B-CLPD)
  2. 2.Role of CD200 in diagnosis , classification and potential value in differential diagnosis
  3. 3.CD200 expression level at different anatomic sites

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2018

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 17, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 19, 2018

Completed
2 months until next milestone

Study Start

First participant enrolled

December 15, 2018

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2020

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
Last Updated

October 19, 2018

Status Verified

October 1, 2018

Enrollment Period

1.7 years

First QC Date

October 17, 2018

Last Update Submit

October 18, 2018

Conditions

Neoplasms

Keywords

chronic lymphoproliferative disorders

Outcome Measures

Primary Outcomes (1)

  • Differential expression of CD200 by using flow cytometric immune-phenotyping in B-chronic lymphoproliferative disorders (B-CLPD)

    Analysis of expression of CD200 in B-CLPDs for differential diagnosis of subtypes of B-CLPDs

    baseline

Interventions

flowcytometryDEVICE

four colour flowcytometry

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All newly diagnosed patients with B-chronic lymphoproliferative disorders

You may qualify if:

  • All newly diagnosed patients with B-chronic lymphoproliferative disorders

You may not qualify if:

  • \) Patient refusal 2) Patients diagnosed T-cell non-hodgkins lymphoma 3) Patients receiving chemo and/or radiotherapy 4) Patients on steroid therapy for any other cause 5) Patients receiving any immunosuppressive drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (5)

  • Ugo V, Leporrier N, Salaun V, Letestu R, Radford-Weiss I, Ramond S, Nataf J, Guesnu M, Picard F, Brouzes C, Perrot JY, Valensi F, Levy V, Ajchenbaum-Cymbalista F, Troussard X. Deciphering leukemic B-cell chronic lymphoproliferative disorders. Leuk Lymphoma. 2006 Oct;47(10):2088-95. doi: 10.1080/10428190600727939.

    PMID: 17071481BACKGROUND

  • Schlette E, Fu K, Medeiros LJ. CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Am J Clin Pathol. 2003 Nov;120(5):760-6. doi: 10.1309/XV4A-G7EM-WQU7-ER67.

    PMID: 14608904BACKGROUND

  • Baseggio L, Traverse-Glehen A, Petinataud F, Callet-Bauchu E, Berger F, Ffrench M, Couris CM, Thieblemont C, Morel D, Coiffier B, Salles G, Felman P. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica. 2010 Apr;95(4):604-12. doi: 10.3324/haematol.2009.011049. Epub 2009 Dec 16.

    PMID: 20015887BACKGROUND

  • Challagundla P, Medeiros LJ, Kanagal-Shamanna R, Miranda RN, Jorgensen JL. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014 Dec;142(6):837-44. doi: 10.1309/AJCPBV9ELXC0ECVL.

    PMID: 25389338BACKGROUND

  • Rygiel TP, Karnam G, Goverse G, van der Marel AP, Greuter MJ, van Schaarenburg RA, Visser WF, Brenkman AB, Molenaar R, Hoek RM, Mebius RE, Meyaard L. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor. Oncogene. 2012 Jun 14;31(24):2979-88. doi: 10.1038/onc.2011.477. Epub 2011 Oct 24.

    PMID: 22020332BACKGROUND

MeSH Terms

Conditions

Neoplasms

Study Officials

  • douaa M Sayed, professor

    South Egypt Cancer Institute

    STUDY DIRECTOR

Central Study Contacts

menna M atef, resident

CONTACT

01025536683menna.abdelaziz9193@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

October 17, 2018

First Posted

October 19, 2018

Study Start

December 15, 2018

Primary Completion

August 30, 2020

Study Completion

April 1, 2021

Last Updated

October 19, 2018

Record last verified: 2018-10